Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

10.0%

1 terminated/withdrawn out of 10 trials

Success Rate

90.0%

+3.5% vs industry average

Late-Stage Pipeline

50%

5 trials in Phase 3/4

Results Transparency

111%

10 of 9 completed trials have results

Key Signals

10 with results

Enrollment Performance

Analytics

Phase 3

5(50.0%)

Phase 1

4(40.0%)

Phase 2

1(10.0%)

10Total

Phase 3(5)

Phase 1(4)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT01523002Phase 1Completed

Drug Interaction Study of Pyronaridine-artesunate & Metoprolol, & Redosing Study of Pyronaridine-artesunate

Role: collaborator

NCT00682630Phase 1Completed

Bioequivalence Trial of Pyronaridine Artesunate To-be-marketed Tablet to the Clinical Trial Reference Tablet

Role: collaborator

NCT01156389Phase 1Completed

Pyronaridine Artesunate-Ritonavir Drug-drug Interaction Study

Role: collaborator

NCT00331136Phase 2Completed

Pyronaridine and Artesunate (3:1) in Children With Acute Uncomplicated Plasmodium Falciparum Malaria

Role: collaborator

NCT04368910Phase 3Terminated

Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria

Role: collaborator

NCT01383109Phase 1Completed

Human Mass Balance Study of Pyronaridine

Role: collaborator

NCT00541385Phase 3Completed

Role: collaborator

NCT00440999Phase 3Completed

Pyronaridine Artesunate (3:1) in Children and Adults With Acute Plasmodium Vivax Malaria

Role: collaborator

NCT00422084Phase 3Completed

Pyronaridine Artesunate (3:1) Versus Coartem® in P Falciparum Malaria Patients

Role: collaborator

NCT00403260Phase 3Completed

Pyronaridine - Artesunate (3:1) Versus Mefloquine Plus Artesunate in Plasmodium Falciparum Malaria Patients

Role: collaborator

All 10 trials loaded